We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$143M
1-Year Est. Return
102.52%
This Fund
S&P 500
This Quarter
Est. Return
+21.15%
1 Year Est. Return
+102.52%
3 Year Est. Return
+167.58%
5 Year Est. Return
+215.85%
10 Year Est. Return
+1,289.38%
AUM
$143M
AUM Growth
+$22.6M
(+19%)
Cap. Flow
+$11.4M
Cap. Flow
% of AUM
7.98%
Top 10 Holdings %
Top 10 Hldgs %
39.65%
Holding
91
New
14
Increased
17
Reduced
18
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$3.03M |
| 2 |
ORKA
Oruka Therapeutics
ORKA
|
+$2.8M |
| 3 |
Summit Therapeutics
SMMT
|
+$2.67M |
| 4 |
CBIO
Crescent Biopharma
CBIO
|
+$2.37M |
| 5 |
DFTX
Definium Therapeutics
DFTX
|
+$1.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EVMN
Evommune Inc
EVMN
|
+$13.5M |
| 2 |
Gilead Sciences
GILD
|
+$905K |
| 3 |
RAPP
Rapport Therapeutics
RAPP
|
+$835K |
| 4 |
BOLD
Boundless Bio
BOLD
|
+$746K |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$698K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
ARS Pharmaceuticals
SPRY
$559M
| $239K | 0.17% |
29,900
-49,250
| -62% | -$424K |
|
77
Structure Therapeutics
GPCR
$3.38B
| $232K | 0.16% |
4,325
-9,777
| -69% | -$433K |
|
78
Medpace
MEDP
$16.5B
| $228K | 0.16% |
430
| – | – |
|
|
TEM
79
Tempus AI
TEM
$11.7B
| $225K | 0.16% |
+3,880
| New | +$195K |
|
80
Corbus Pharmaceuticals
CRBP
$214M
| $188K | 0.13% |
+20,000
| New | +$189K |
|
81
Palisade Bio
PALI
$364M
| $184K | 0.13% |
88,000
| – | – |
|
82
enGene Therapeutics
ENGN
$122M
| $37.5K | 0.03% |
+21,700
| New | +$88.5K |
|
83
Alignment Healthcare
ALHC
$2.81B
| – | – |
-26,911
| Closed | -$474K |
|
84
Inspire Medical Systems
INSP
$1.82B
| – | – |
-7,225
| Closed | -$373K |
|
85
Neurocrine Biosciences
NBIX
$15.8B
| – | – |
-2,300
| Closed | -$344K |
|
86
uniQure
QURE
$3.09B
| – | – |
-29,245
| Closed | -$499K |
|
87
RadNet
RDNT
$5.8B
| – | – |
-7,999
| Closed | -$447K |
|
|
BOLD
88
Boundless Bio
BOLD
$65.3M
| – | – |
-678,574
| Closed | -$746K |
|
|
RAPP
89
Rapport Therapeutics
RAPP
$2.2B
| – | – |
-25,421
| Closed | -$835K |
|
|
OMDA
90
Omada Health Inc
OMDA
$1.39B
| – | – |
-25,620
| Closed | -$322K |
|
|
EVMN
91
Evommune Inc
EVMN
$445M
| – | – |
-589,005
| Closed | -$13.5M |
|
Similar funds
ICMP
JPT
SL
PWM
BOM
AVA
FPC
ACP
Sectoral Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sectoral Asset Management held 91 positions worth $143M, up 19% from $121M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Sectoral Asset Management deployed $11.4M of net new capital in Q2 2026, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was iRhythm Holdings: 26,070 shares worth $3.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Gilead Sciences, an estimated $905K trimmed.
- Sectoral Asset Management's largest Q2 2026 buy was iRhythm Holdings: 26,070 shares worth $3.1M.
- Sectoral Asset Management added most to Summit Therapeutics in Q2 2026, an estimated $2.67M increase.
- Sectoral Asset Management's biggest Q2 2026 reduction was Gilead Sciences, cutting an estimated $905K.
- Sectoral Asset Management fully exited Evommune Inc in Q2 2026, selling an estimated $13.5M.
- Sectoral Asset Management's ten largest holdings make up 40% of its $143M portfolio in Q2 2026.
- Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2026.
- Sectoral Asset Management's portfolio value rose 19% quarter-over-quarter to $143M.
Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.